Saltar al contenido
Merck
Todas las fotos(2)

Key Documents

View All Documentation

L5918

Sigma-Aldrich

Lomustine

≥98%

Sinónimos:

1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(2)

About This Item

Fórmula empírica (notación de Hill):
C9H16ClN3O2
Número de CAS:
13010-47-4
Peso molecular:
233.70
EC Number:
235-859-2
MDL number:
MFCD00012392
UNSPSC Code:
12352100
PubChem Substance ID:
329817632
NACRES:
NA.25

assay

≥98%

storage temp.

−20°C

SMILES string

ClCCN(N=O)C(=O)NC1CCCCC1

InChI

1S/C9H16ClN3O2/c10-6-7-13(12-15)9(14)11-8-4-2-1-3-5-8/h8H,1-7H2,(H,11,14)

Inchi Key

GQYIWUVLTXOXAJ-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Biochem/physiol Actions

Antineoplastic agent with cellular DNA effects. Lomustine induces p53 expression in A2870 cells.

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

hcodes

H301,H350

Hazard Classifications

Acute Tox. 3 Oral - Carc. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Joann L Ater et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(21), 2641-2647 (2012-06-06)
PURPOSE Surgery is curative therapy for pediatric low-grade gliomas (LGGs) in areas of the brain amenable to complete resection. However, LGGs located in areas where complete resection is not possible can threaten both function and life. The purpose of this
Enrico Franceschi et al.
Neuro-oncology, 14(12), 1503-1510 (2012-10-24)
The treatment of patients with recurrent glioblastoma remains a major oncologic problem, with median survival after progression of 7-9 months. To determine the maximum tolerated dose and dose-limiting toxicity (DLT), the combination of dasatinib and cyclonexyl-chloroethyl-nitrosourea (CCNU) was investigated in
Carsten Friedrich et al.
European journal of cancer (Oxford, England : 1990), 49(4), 893-903 (2012-11-28)
Medulloblastoma in adulthood is rare. Knowledge is limited, and the efficacy and toxicity of chemotherapy--especially in nonmetastatic disease--is still elusive. Seventy adults aged ≥21 years (median age: 28.5 years) with nonmetastatic medulloblastoma were followed as observational patients within the prospective
Daisuke Hasegawa et al.
The Journal of veterinary medical science, 74(11), 1517-1521 (2012-07-13)
A 9 year-old, neutered, male French Bulldog showing cluster seizures was diagnosed with a glioma in the right piriform cortex by MRI. Hypofractionated radiation therapy (RT) was performed using a linear accelerator. Although the lesion had involuted significantly at 2
Tracy T Batchelor et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(26), 3212-3218 (2013-08-14)
A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recent in in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as monotherapy
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico